Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.33 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.33 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19711172 | 0.79 | BAZ2B (0.37) | BRD4ATAD2BAZ2BBAZ2AKDM4E | |
| SCHEMBL22448626 | 0.78 | LMNA (0.39) | ALDH1A1ATAD2LMNAGAAHPGD | |
| SCHEMBL24759404 | 0.78 | ALDH1A1 (0.33) | ALDH1A1LMNAHSD17B10GAAGPR55 | |
| SCHEMBL26237165 | 0.76 | HDAC6 (0.33) | ATAD2CREBBP | |
| SCHEMBL13481160 | 0.75 | ATAD2 (0.39) | BRD4ATAD2BAZ2BBAZ2AKDM4E | |
| SCHEMBL20906890 | 0.75 | NOTUM (0.38) | ATAD2CREBBP | |
| SCHEMBL26024529 | 0.73 | KDM4E (0.38) | ALDH1A1ATAD2HSD17B10GAAKDM4E | |
| SCHEMBL12172358 | 0.70 | MAP2K2 (0.39) | BRD4ATAD2BAZ2BBAZ2AKDM4E | |
| SCHEMBL15535707 | 0.70 | ATAD2 (0.45) | ALDH1A1BRD4ATAD2HSD17B10GAA | |
| SCHEMBL6239638 | 0.70 | BRD4 (0.36) | BRD4ATAD2BAZ2BBAZ2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | PIK3R3, JAK2, JAK3 | ALDH1A1 3131/4885BRD4 32/4885ATAD2 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.